Apogee Therapeutics Inc (APGE) PT Raised to $86 at Jefferies

Jefferies analyst Akash Tewari raised the price target on Apogee Therapeutics Inc (NASDAQ: APGE) to $86.00 (from $82.00) while maintaining a Buy rating.

The analyst comments "APG990 (OX40L) SAD showed 1) ~60d human t1/2, which mgmt believes can do Q3-6M maintenance dosing; 2) no pyrexia/chills; 3) combo w/anti-IL13 '777 showed no preclin tox studies at 3mo; 4) APGE is confident they can co-form IL13/OX40 in 2mL. APGE is running Ph.1b in AD for IL13/OX40L combo vs Dupi (data exp 2H'26) & noted 10pt improvement would be a numerical win (trial isn't powered for superiority). We're incr our '990 PS to $1.8Bn; PT $82->$86."

You May Also Be Interested In

• Resideo Technologies (REZI) PT Lowered to $27 at Oppenheimer
• Macquarie Upgrades Inventec Corp (2356:TT) to Neutral
• Academy Sports and Outdoor (ASO) 3600 contracts of August 52 calls trade